How to Use
Ingredients
Cross-linked hyaluronic acid (in phosphate buffer) with 0.3% lidocaine.
Safety Information
- Prescription use only
- Directions for Use for full administration guidance and safety information are available at obagi.com/saypha
- Approved Use: Indicated for injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds) in adults over the age of 21
- The most commonly observed side effects include tenderness, swelling, firmness, lumps/bumps, pain, bruising, redness, itching at the injection site, and headache. To learn more about serious but rare side effects and full Important Safety Information, visit obagi.com/saypha
- To report a side effect with any Saypha® product, please call Obagi® Customer Support at 1-888-798-9809
INTELLECTUAL PROPERTY
- For patent information, visit obagi.com/saypha.
- saypha® is a registered trademark of Croma-Pharma GmbH used under license.
- Obagi® and all derivatives are registered trademarks of Obagi Cosmeceuticals LLC.
- All other products/brand names, whether designated by notice or not, are trademarks of their respective owners.
Clinical Data
- In a U.S. pivotal study of 483 randomized subjects (322 treated with ChIQ™, 161 with Control), ChIQ™ met its primary effectiveness endpoint, demonstrating non-inferiority to Juvderm Voluma for correction of midface volume deficit at 24 weeks (87.9% of ChIQ™ subjects vs. 83.9% of Control subjects were MVDSS responders; p <0.0001).
- At 12 months, Obagi saypha ChIQ patients were numerically more likely to maintain improvement, with over 72% still responding.**
* This summary reflects the clinical trial as conducted and reported by Croma-Pharma®. Obagi® Medical was not involved in this research, and all information provided originates from Croma-Pharma®. ** MVDSS responder rate at Week 48; Obagi saypha 1.saypha ChIQ. Directions for Use. Croma-Pharma GmbH; 2026.